Braskem SA
BAKACTIVE ACQUIRERQUIETBraskem SA reads as an Active Acquirer (composite 49/100); Transformational Buyer deploying $279M across 0 disclosed transactions, newly disclosed vs the prior cycle · primary market Chemicals & Materials.
Lens
Disclosed M&A capital (2023–2025)
$279M
vs N/A in 2020–2022
Disclosed transactions
N/A
1/3 active fiscal years in window
Buyer archetype
Transformational Buyer
Episodic but very large disclosed transactions drive the profile.
Composite score
49
Active Acquirer dominates · Quiet
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
DominantCompanies actively deploying disclosed capital into M&A
- $4.3B disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 36d
Target Probability
Issuers showing target-side patterns from filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
Pressure Watch
Issuers facing activism, governance, or control pressure
Distress Watch
Issuers showing financial-distress filing patterns
- Missing recent 10-Q
Restatement Risk
Issuers with accounting-integrity flags from filings
Capital Velocity
Issuers with the highest filing-activity intensity
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $68B
- 1 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $2,406M · Peak count: 1
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A |
| 2023 | N/A | $279M | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A |
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“Our class A preferred shares and the ADSs have limited voting rights and are not entitled to vote to approve corporate transactions, including mergers or consolidations of our company with other companies, or the declaration of dividends.”
“we have fully consolidated the results of Copesul and its subsidiaries into our financial statements as from April 1, 2007”
“Under the Brazilian Corporation Law and our by-laws, holders of our class A preferred shares and, consequently, the ADSs are not entitled to vote at meetings of our shareholders, except in very limited circumstances. These limited circumstances directly relate to key rights of the holders of class A preferred shares, such as modifying basic terms of our class A preferred shares or creating a new class of preferred shares with superior rights. Holders of preferred shares without voting rights are entitled to elect one member and his or her respective alternate to our board of directors and our fiscal council. Holders of our class A preferred shares and the ADSs are not entitled to vote to approve corporate transactions, including mergers or consolidations of our company with other companies, or the declaration of dividends. See “Item 10. Additional Information—Description of Our Company’s By-laws—Voting Rights.””
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Chemicals & Materials
- Market spend (2023–2025)
- $85.8B
- Market spend (2020–2022)
- $80.5B
- Recent vs prior
- +7%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
BAK trades at a +89.6-turn premium to the Chemicals & Materials peer median of 15.9×.
- EV / Revenue
- 1.0×
- Net debt / EBITDA
- N/A
- Peer median EV / EBITDA
- 15.9×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
Braskem SABAK | 105.6× | 1.0× | N/A | $69.3B | $279M |
Ecolab Inc.ECL | 24.5× | 4.9× | 2.3× | $16.5B | $2.1B |
| 15.9× | 5.2× | 0.0× | $8.1B | $2.3B | |
| 13.4× | 2.4× | 0.3× | $10.8B | N/A |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Chemicals & Materials. Bars scaled to the highest EV/EBITDA in the set.
Target landscape.
Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.
No qualifying public-issuer targets surfaced from the current signal mix.
Stated target categories
No target categories enumerated in the audited corpus for this issuer.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)292026-04-20
- 10-Q (quarterly)0N/A
- 8-K (event)0N/A
- Proxy / DEF 14A0N/A
- Activism (13D / DFAN / PREC)0N/A
Signals on file
- info
Signal
Serial acquisition history
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.